Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 1, 2008, Pages 25-32

  Müller, Ingo ^a   Kordowich, Sandra ^a   Holzwarth, Christina ^a   Isensee, Gesa ^a   Lang, Peter ^a   Neunhoeffer, Felix ^a   Dominici, Massimo ^b   Greil, Johann ^c   Handgretinger, Rupert ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Multipotent mesenchymal stromal cell; Pediatrics; Stem cell; Transplantation

Indexed keywords

BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL ISOLATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; ERYTHROPHAGOCYTOSIS; FOLLOW UP; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT MESENCHYMAL STROMAL CELL TRANSPLANTATION; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REOPERATION; STROMAL CELLS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 36749056828     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.06.021     Document Type: Article

References (31)

1. Galotto M., et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp. Hematol. 27 (1999) 1460-1466
2. Rieger K., et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp. Hematol. 33 (2005) 605-611
3. Wang J., Liu K., and Lu D.P. Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin. Int. J. Hematol. 82 (2005) 152-158
4. Poloni A., et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 20 (2006) 329-335
5. Pozzi S., et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp. Hematol. 34 (2006) 934-942
6. Horwitz E.M., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8932-8937
7. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
8. Krampera M., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
9. Di Nicola M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
10. Krampera M., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
11. Sotiropoulou P.A., Perez S.A., Salagianni M., Baxevanis C.N., and Papamichail M. Response to the "Letter to the Editor" by Dr. Dimarakis et al, entitled: Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells 24 (2006) 1409-1410
12. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
13. Krampera M., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006) 386-398
14. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
15. Rasmusson I., Ringden O., Sundberg B., and Le B.K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305 (2005) 33-41
16. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., and Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
17. Lazarus H.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398
18. Le Blanc K., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
19. Wang Y., et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7 (2005) 509-519
20. Lazarus H.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398
21. Ringden O., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
22. Pozzi S., et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp. Hematol. 34 (2006) 934-942
23. Le Blanc K., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
24. MacMillan M.L., Ramsay N.K.C., Atkinson K., and Wagner J.E. Ex-vivo culture-expanded parental haploidentical mesenchymal stem cells (MSC) to promote engraftment in recipients of unrelated donor umbilical cord blood (UCB): results of a phase I-II clinical trial. Blood 100 (2002) 837a (Ref Type: Abstract)
25. Maccario R., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
26. Muller I., et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8 (2006) 437-444
27. Hofling A.A., Vogler C., Creer M.H., and Sands M.S. Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood 101 (2003) 2054-2063
28. Shultz L.D., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174 (2005) 6477-6489
29. Maccario R., et al. Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol. Blood Marrow Transplant. 11 (2005) 1031-1032
30. Ringden O., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
31. Lazarus H.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398